Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Stephen Yates"'
Autor:
Stephen Yates
Christians look with hope to the resurrection of the dead and the restoration of all things. But what of those who have already died? Do they also await these things, or have they in some sense already happened for them? Within the Catholic theologic
Publikováno v:
Pharmaceuticals, Vol 13, Iss 9, p 219 (2020)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic
Externí odkaz:
https://doaj.org/article/c232b18773a94e3fbad4c4040432062b
Publikováno v:
Neurology. 99:S42-S43
ObjectiveTo evaluate efficacy and safety of rozanolixizumab for treatment of leucine-rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AIE).BackgroundLGI1 AIE is a clinically homogeneous syndrome mediated by autoantibodies, predominantly of t
Autor:
Andrew Stephen Yates, Blair William Gibbs, Saoirse E. O'Sullivan, Nicholas James Clarkson, Jonathan Paul Liebling
Publikováno v:
Cannabis Cannabinoid Res
INTRODUCTION: Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or conta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be86fca2ddd89bea14039b96c4c1485d
https://europepmc.org/articles/PMC9070743/
https://europepmc.org/articles/PMC9070743/
Autor:
Michele Teufel, TransCelerate Biopharma Toolkits Core Team, Anne Marie L Inglis, M. Elmer, Kathyjo Shay, Catherine Sutherland, Stephen Yates, Cathy Florek, Sean Ludlam, Tanja Keiper, Karen L Johnson, T J Sharpe, Fabian Somers, Alison Greene, Lori Gabryelski
Publikováno v:
Therapeutic Innovation & Regulatory Science
Incorporating patient perspectives into clinical studies is recognized as important to the development of high-quality, safe, and effective fit-for-patient medicines. However, no widely accepted methodology to help design more patient-centered studie
Publikováno v:
Epilepsia
Objective To evaluate long‐term safety/tolerability of brivaracetam at individualized doses ≤200 mg/d (primary) and maintenance of efficacy over time (secondary) in adults with focal seizures or primary generalized seizures (PGS) enrolled in phas
Publikováno v:
Molecules, Vol 26, Iss 6178, p 6178 (2021)
The cannabinoid 1 (CB1) receptor regulates appetite and body weight; however, unwanted central side effects of both agonists (in wasting disorders) or antagonists (in obesity and diabetes) have limited their therapeutic utility. At the peripheral lev
Autor:
Timothy J. England, Z.D. Bellman, Sophie A. Millar, Andrew Stephen Yates, Nicole L. Stone, Saoirse E. O'Sullivan
Publikováno v:
British Journal of Clinical Pharmacology
Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have bee
Autor:
Khaled Alamri, Molly L. Aldridge, Larry Alphs, Barbara E. Bierer, Eric P. Borrelli, Jaclyn L.F. Bosco, Nicholas Brooke, Emily S. Brouwer, Aisling R. Caffrey, Alicyn Campbell, Timothy S. Carey, Wendy Camelo Castillo, John Chaplin, Jennifer B. Christian, Thomas W. Concannon, Catherine Copley-Merriman, Kourtney Davis, Robert S. Epstein, Nicolle M. Gatto, Cynthia J. Girman, Rolf H.H. Groenwold, Cynthia Grossman, Kristen A. Hahn, Anne Marie Hamior, Katherine E. Harris, Ehab Hasan, Austin R. Horn, Phyo T. Htoo, Kristy Iglay, Michele Jonsson Funk, Sylvia Baedorf Kassis, Bray Patrick Lake, Suzanne N. Landi, Craig Lipset, Vincent Lo Re, Jennifer L. Lund, Kenneth Man, Elizabeth Manning, Leah McGrath, Michelle Medeiros, Marilyn A. Metcalf, Margaret Mordin, Mary Stober Murray, Nabil Natafgi, Catherine A. Panozzo, Jeanne M. Pimenta, Sudha R. Raman, Jeanne M. Regnante, Nicole A. Richie, Mary E. Ritchey, Jamie Roberts, Ify Sargeant, Roslyn F. Schneider, Suzanne Schrandt, Joe V. Selby, Soko Setoguchi, Ju-Young (Judy) Shin, Joanna Siegel, Fabian Somers, Komathi Stem, Til Stürmer, Elizabeth A. Suarez, J. Russell Teagarden, Kevin E. Thorpe, Lina Titievsky, Andrea B. Troxel, Priscilla Velentgas, Cunlin Wang, Jenna Wong, Stephen Yates, Guy Yeoman, Wei Zhou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfe115e0e1fb3d212f5d186895ac3cf3
https://doi.org/10.1016/b978-0-12-817663-4.01002-3
https://doi.org/10.1016/b978-0-12-817663-4.01002-3
Autor:
Bray Patrick Lake, Nicholas Brooke, Jamie Roberts, Cynthia Grossman, Anne Marie Hamior, Elizabeth Manning, Roslyn F. Schneider, Fabian Somers, Nicole Richie, Stephen Yates, Alicyn Campbell, Sylvia Baedorf Kassis, Jeanne M. Regnante, Barbara E. Bierer, Guy Yeoman, Suzanne Schrandt, Ify Sargeant, Mary Stober Murray, Marilyn A. Metcalf, Craig Lipset
In this Chapter, Patient Voice in Clinical Trial Programs in Industry, we argue that the Life Sciences industry must adapt if they are to succeed and make medicines with (rather than just for) patients. Those companies able to deliver medicines and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e570bffeaf1266249cced0186aa21eb
https://doi.org/10.1016/b978-0-12-817663-4.00026-x
https://doi.org/10.1016/b978-0-12-817663-4.00026-x